RemeGen CEO on H.K. IPO, Strategy, Drugs in Pipeline

The transcript discusses a biopharma company's successful IPO in Hong Kong, highlighting its plans for future clinical studies and manufacturing expansion. It addresses market enthusiasm for biopharma, emphasizing the potential for continued support. The company outlines its drug pipeline, focusing on two key drugs, RC 18 and telitacicept, and their development stages. The discussion also covers profitability prospects, market potential, and the possibility of future partnerships with other companies.

What is the anticipated timeline for drug approval in China?

What are the expected outcomes of the drugs mentioned in terms of market potential?

What potential partnerships are being discussed for the future?